Most (> 96%) patients reported ED of at least 1-year duration.

Color Shade Approximate Dose Additional Features Notes
Bright Yellow 100 mg High concentration Prescription-only
Pale Yellow 25 mg Lower dose Suitable for sensitive users
Deep Amber 50 mg Standard dose Most common

The primary efficacy and safety study conducted outside the US included 268 patients, with a mean age of 56 years (range 21 to 78 years). Ninety-three percent of patients reported ED of at least 1-year duration. In each of these trials, conducted without regard to the timing of dose and sexual intercourse, tadalafil demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 17). When taken as directed, tadalafil was effective at improving erectile function. In the 6 month double-blind study, the treatment effect of tadalafil did not diminish over time. Table 17: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Tadalafil for Once Daily Use Studies Efficacy Results in ED Patients with Diabetes Mellitus — Tadalafil for once daily use was shown to be effective in treating ED in patients with diabetes mellitus. In this third trial, tadalafil demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 18).

Warnings & Precautions

Efficacy Results in Patients with BPH initiating Tadalafil and Finasteride – Tadalafil for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an enlarged prostate (> 30 cc) for up to 26 weeks. Tadalafil with finasteride demonstrated statistically significant improvement in the signs and symptoms of BPH compared to placebo with finasteride, as measured by the total IPSS at 12 weeks, the primary study endpoint (see Table 20). The incremental benefit of tadalafil beyond 26 weeks is unknown. Table 20: Mean Total IPSS Changes in BPH Patients in a Tadalafil for Once Daily Use Study Together with Finasteride Figure 7: Mean Total IPSS Changes By Visit in BPH Patients Taking Tadalafil for Once Daily Use Together With Finasteride In the 404 patients who had both ED and BPH at baseline, changes in erectile function were assessed as key secondary endpoints using the EF domain of the IIEF questionnaire. A statistically significant improvement from baseline (tadalafil/finasteride 13.7, placebo/finasteride 15.1) was observed at week 4 (tadalafil/finasteride 3.7, placebo/finasteride -1.1; p<.001), week 12 (tadalafil/finasteride 4.7, placebo/finasteride 0.6; p<.001), and week 26 (tadalafil/finasteride 4.7, placebo/finasteride 0.0; p<.001).

Overall Rating

The efficacy and safety of tadalafil for once daily use for the treatment of ED, and the signs and symptoms of BPH, in patients with both conditions was evaluated in one placebo-controlled, multinational, double-blind, parallel-arm study which randomized 606 patients to receive either tadalafil 2.5 mg, 5 mg, for once daily use or placebo. In this study, the co-primary endpoints were total IPSS and the Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF). The efficacy results for patients with both ED and BPH, who received either tadalafil 5 mg for once daily use or placebo (N=408) are shown in Tables 21 and 22 and Figure 8. Tadalafil 5 mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EF domain of the IIEF questionnaire. Tadalafil 2.5 mg did not result in statistically significant improvement in the total IPSS.

Marketing and sales

Table 21: Mean IPSS and IIEF EF Domain Changes in the Tadalafil 5 mg for Once Daily Use Study in Patients with ED and BPH Table 22: Mean SEP Question 3 Changes in the Tadalafil 5 mg for Once Daily Use Study in Patients with ED and BPH Tadalafil for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment (see Figure 8). Figure 8: Mean IPSS Changes in ED/BPH Patients by Visit in Study L In this study, the effect of tadalafil 5 mg once daily on Qmax was evaluated as a safety endpoint. 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How SuppliedTadalafil Tablets USP, 2.5 mg are supplied as buy viagra with dapoxetine white to off-white, round, biconvex, film-coated tablets debossed with “C1” on one side and plain on the other.They are available as follows:Bottles of 30: NDC 69238-1346-3Tadalafil Tablets USP, 5 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “A13” on one side and plain on the other.They are available as follows:Bottles of 30: NDC 69238-1347-3Tadalafil Tablets USP, 10 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “AC” above “06” on one side and plain on the other.They are available as follows:Bottles of 30: NDC 69238-1348-3Tadalafil Tablets USP, 20 mg are supplied as yellow colored, oval, biconvex, film-coated tablets debossed with “AA” on one side and “09” on the other.They are available as follows:Bottles of 30: NDC 69238-1349-3 Tadalafil Tablets USP, 2.5 mg are supplied as white to off-white, round, biconvex, film-coated tablets debossed with “C1” on one side and plain on the other. Bottles of 30: NDC 69238-1346-3 Tadalafil Tablets USP, 5 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “A13” on one side and plain on the other. Bottles of 30: NDC 69238-1347-3 Tadalafil Tablets USP, 10 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “AC” above “06” on one side and plain on the other. Table 18: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Tadalafil for Once Daily Use Study in ED Patients with Diabetes The efficacy and safety of tadalafil for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration. The primary efficacy endpoint in the two studies that evaluated the effect of tadalafil for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization.

Product Dosage Quantity + Bonus Price
Viagra Super Active100mg120 + 16 Pills198.37€ 188.92€
Viagra Generic150mg120 + 8 Pills177.58€ 169.12€
Viagra Oral Jelly100mg30 + 5 Sachets115.76€ 110.25€
Viagra Generic25mg360 + 10 Pills213.68€ 203.50€
Viagra Generic50mg20 Pills40.52€ 38.59€
Viagra Super Active100mg180 + 20 Pills280.97€ 267.59€
Viagra Generic150mg360 + 10 Pills423.48€ 403.31€
Viagra Generic200mg20 Pills61.69€ 58.75€
Viagra Generic25mg60 + 4 Pills71.99€ 68.56€
Viagra Original100mg4 Pills40.94€ 38.99€
Viagra Generic150mg180 + 10 Pills236.46€ 225.20€
Viagra Generic200mg60 + 4 Pills125.19€ 119.23€
Viagra Super Active100mg20 + 4 Pills48.05€ 45.76€
Viagra Generic200mg180 + 10 Pills277.56€ 264.34€
Viagra Generic50mg60 + 4 Pills83.93€ 79.93€
Viagra Soft Tabs100mg10 Pills36.93€ 35.17€

The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87) who received either tadalafil 5 mg for once daily use or placebo (N=748) in Studies J and K are shown in Table 19 and Figures 5 and 6, respectively.

How much does Sildenafil (Viagra) cost?

Bottles of 30: NDC 69238-1348-3 Tadalafil Tablets USP, 20 mg are supplied as yellow colored, oval, biconvex, film-coated tablets debossed with “AA” on one side and “09” on the other. Bottles of 30: NDC 69238-1349-3 17 PATIENT COUNSELING INFORMATION “See FDA-approved patient labeling (Patient Information)”.17.1 NitratesPhysicians should discuss with patients the contraindication of tadalafil with regular and/or intermittent use of organic nitrates. Patients should be counseled that concomitant use of tadalafil with nitrates could cause blood pressure to suddenly drop to an unsafe level, resulting in dizziness, syncope, or even heart attack or stroke.Physicians should discuss with patients the appropriate action in the event that they experience anginal chest pain requiring nitroglycerin following intake of tadalafil. Therefore, patients who experience anginal chest pain after taking tadalafil should seek immediate medical attention [see Contraindications (4.1) and Warnings and Precautions (5.1)].17.2 Guanylate Cyclase (GC) StimulatorsPhysicians should discuss with patients the contraindication of tadalafil with any use of a GC stimulator, such as riociguat, for pulmonary arterial hypertension. Patients should be counseled that the concomitant use of tadalafil with GC stimulators may cause blood pressure to drop to an unsafe level.17.3 Cardiovascular ConsiderationsPhysicians should consider the potential cardiac risk of sexual activity in patients with preexisting cardiovascular disease.

Pros of Cialis

Physicians should advise patients who experience symptoms upon initiation of sexual activity to refrain from further sexual activity and seek immediate medical attention [see Warnings and Precautions (5.1)].17.4 Concomitant Use with Drugs Which Lower Blood PressurePhysicians should discuss with patients the potential for tadalafil to augment the blood-pressure-lowering effect of alpha-blockers, and antihypertensive medications [see Warnings and Precautions (5.6), Drug Interactions (7.1), and Clinical Pharmacology (12.2)].17.5 Potential for Drug Interactions When Taking Tadalafil Tablets for Once Daily UsePhysicians should discuss with patients the clinical implications of continuous exposure to tadalafil when prescribing tadalafil tablets for once daily use, especially the potential for interactions with medications (e.g., nitrates, alpha-blockers, antihypertensives and potent inhibitors of cytochrome P450 3A4) and with substantial consumption of alcohol [see Dosage and Administration (2.7), Warnings and Precautions (5.6), Drug Interactions (7.1, 7.2), Clinical Pharmacology (12.2), and Clinical Studies (14.2)].17.6 PriapismThere have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.

How ED meds work: A refresher

In each of these 2 trials, tadalafil 5 mg for once daily use resulted in statistically significant improvement in the total IPSS compared viagra tablet for sex to placebo. Table 19: Mean IPSS Changes in BPH Patients in Two Tadalafil for Once Daily Use Studies Figure 5: Mean IPSS Changes in BPH Patients by Visit in Study J Figure 6: Mean IPSS Changes in BPH Patients by Visit in Study K In Study J, the effect of tadalafil 5 mg once daily on maximum urinary flow rate (Qmax) was evaluated as a secondary efficacy endpoint. In Study K, the effect of tadalafil 5 mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (tadalafil 5 mg: 1.6 mL/sec, placebo: 1.1 mL/sec); however, these changes were not significantly different between groups. Efficacy Results in Patients with BPH initiating Tadalafil and Finasteride – Tadalafil for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an enlarged prostate (> 30 cc) for up to 26 weeks. Tadalafil with finasteride demonstrated statistically significant improvement in the signs and symptoms of BPH compared to placebo with finasteride, as measured by the total IPSS at 12 weeks, the primary study endpoint (see Table 20). The incremental benefit of tadalafil beyond 26 weeks is unknown. Table 20: Mean Total IPSS Changes in BPH Patients in a Tadalafil for Once Daily Use Study Together with Finasteride Figure 7: Mean Total IPSS Changes By Visit in BPH Patients Taking Tadalafil for Once Daily Use Together With Finasteride In the 404 patients who had both ED and BPH at baseline, changes in erectile function were assessed as key secondary endpoints using the EF domain of the IIEF questionnaire. A statistically significant improvement from baseline (tadalafil/finasteride 13.7, placebo/finasteride 15.1) was observed at week 4 (tadalafil/finasteride 3.7, placebo/finasteride -1.1; p<.001), week 12 (tadalafil/finasteride 4.7, placebo/finasteride 0.6; p<.001), and week 26 (tadalafil/finasteride 4.7, placebo/finasteride 0.0; p<.001). The efficacy and safety of tadalafil for once daily use for the treatment of ED, and the signs and symptoms of BPH, in patients with both conditions was evaluated in one placebo-controlled, multinational, double-blind, parallel-arm study which randomized 606 patients to receive either tadalafil 2.5 mg, 5 mg, for once daily use or placebo.

  • The color yellow helps distinguish Viagra pills from other ED medications.
  • Some yellow Viagra tablets are designed for extended-release effects.
  • It's essential to purchase from reliable sources to avoid counterfeit pills.
  • Viagra works by inhibiting an enzyme called PDE5, enhancing blood flow.
  • Missing doses or inconsistent use can reduce treatment effectiveness.
  • Always read the patient information leaflet included with the pill.

In this study, the co-primary endpoints were total IPSS and the Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF). The efficacy results for patients with both ED and BPH, who received either tadalafil 5 mg for once daily use or placebo (N=408) are shown in Tables 21 and 22 and Figure 8.

2.6 Use in Specific Populations

Professional resources

Tadalafil 5 mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EF domain of the IIEF questionnaire. Tadalafil 2.5 mg did not result in statistically significant improvement in the total IPSS. Table 21: Mean IPSS and IIEF EF Domain Changes in the Tadalafil 5 mg for Once Daily Use Study in Patients with ED and BPH Table 22: Mean SEP Question 3 Changes in the Tadalafil 5 mg for Once Daily Use Study in Patients with ED and BPH Tadalafil for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment (see Figure 8). Figure 8: Mean IPSS Changes in ED/BPH Patients by Visit in Study L In this study, the effect of tadalafil 5 mg once daily on Qmax was evaluated as a safety endpoint.

  • The manufacturing date and expiry date are critical for pill safety.
  • Yellow Viagra pills can sometimes be found in various doses, requiring cautious use.
  • Combining Viagra with recreational drugs can cause dangerous interactions.
  • Medical professionals recommend a thorough health assessment before starting treatment.
  • The pill may cause temporary changes in vision, requiring caution during activities.
  • Use only as directed by a healthcare provider to minimize risks.

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How SuppliedTadalafil Tablets USP, 2.5 mg are supplied as buy viagra with dapoxetine white to off-white, round, biconvex, film-coated tablets debossed with “C1” on one side and plain on the other.They are available as follows:Bottles of 30: NDC 69238-1346-3Tadalafil Tablets USP, 5 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “A13” on one side and plain on the other.They are available as follows:Bottles of 30: NDC 69238-1347-3Tadalafil Tablets USP, 10 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “AC” above “06” on one side and plain on the other.They are available as follows:Bottles of 30: NDC 69238-1348-3Tadalafil Tablets USP, 20 mg are supplied as yellow colored, oval, biconvex, film-coated tablets debossed with “AA” on one side and “09” on the other.They are available as follows:Bottles of 30: NDC 69238-1349-3 Tadalafil Tablets USP, 2.5 mg are supplied as white to off-white, round, biconvex, film-coated tablets debossed with “C1” on one side and plain on the other.

  • Yellow Viagra should be stored out of reach of children and pets.
  • It is not suitable for use in individuals with severe hypotension or stroke history.
  • The medication can cause priapism, a prolonged erection that requires medical attention.
  • Do not take yellow Viagra if you are allergic to sildenafil or other ingredients.
  • The pill's nutritional compatibility is generally unaffected by diet unless high-fat.
  • Discontinue use and seek medical help if adverse reactions occur.

Bottles of 30: NDC 69238-1346-3 Tadalafil Tablets USP, 5 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “A13” on one side and plain on the other.

5.5 Sudden Hearing Loss

Most (> 96%) patients reported ED of at least 1-year duration. The primary efficacy and safety study conducted outside the US included 268 patients, with a mean age of 56 years (range 21 to 78 years). Ninety-three percent of patients reported ED of at least 1-year duration. In each of these trials, conducted without regard to the timing of dose and sexual intercourse, tadalafil demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 17). When taken as directed, tadalafil was effective at improving erectile function.

Does insurance cover ED pills?

In the 6 month double-blind study, the treatment effect of tadalafil did not diminish over time. Table 17: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Tadalafil for Once Daily Use Studies Efficacy Results in ED Patients with Diabetes Mellitus — Tadalafil for once daily use was shown to be effective in treating ED in patients with diabetes mellitus. In this third trial, tadalafil demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 18). Table 18: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Tadalafil for Once Daily Use Study in ED Patients with Diabetes The efficacy and safety of tadalafil for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration. The primary efficacy endpoint in the two studies that evaluated the effect of tadalafil for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization.

Regional issues

The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87) who received either tadalafil 5 mg for once daily use or placebo (N=748) in Studies J and K are shown in Table 19 and Figures 5 and 6, respectively. In each of these 2 trials, tadalafil 5 mg for once daily use resulted in statistically significant improvement in the total IPSS compared viagra tablet for sex to placebo. Table 19: Mean IPSS Changes in BPH Patients in Two Tadalafil for Once Daily Use Studies Figure 5: Mean IPSS Changes in BPH Patients by Visit in Study J Figure 6: Mean IPSS Changes in BPH Patients by Visit in Study K In Study J, the effect of tadalafil 5 mg once daily on maximum urinary flow rate (Qmax) was evaluated as a secondary efficacy endpoint. In Study K, the effect of tadalafil 5 mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (tadalafil 5 mg: 1.6 mL/sec, placebo: 1.1 mL/sec); however, these changes were not significantly different between groups. Bottles of 30: NDC 69238-1347-3 Tadalafil Tablets USP, 10 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “AC” above “06” on one side and plain on the other. Bottles of 30: NDC 69238-1348-3 Tadalafil Tablets USP, 20 mg are supplied as yellow colored, oval, biconvex, film-coated tablets debossed with “AA” on one side and “09” on the other. Bottles of 30: NDC 69238-1349-3 17 PATIENT COUNSELING INFORMATION “See FDA-approved patient labeling (Patient Information)”.17.1 NitratesPhysicians should discuss with patients the contraindication of tadalafil with regular and/or intermittent use of organic nitrates.

  • Yellow Viagra pills are often found online, but beware of counterfeit products.
  • Authentic pills are manufactured under strict quality control standards.
  • The medication is not an aphrodisiac; it requires sexual stimulation to work.
  • Do not combine Viagra with alcohol, as it can worsen side effects.
  • People with certain health conditions should avoid using Viagra without consulting a doctor.
  • Yellow Viagra pills can be part of treatment for erectile dysfunction caused by health issues.

Patients should be counseled that concomitant use of tadalafil with nitrates could cause blood pressure to suddenly drop to an unsafe level, resulting in dizziness, syncope, or even heart attack or stroke.Physicians should discuss with patients the appropriate action in the event that they experience anginal chest pain requiring nitroglycerin following intake of tadalafil. Therefore, patients who experience anginal chest pain after taking tadalafil should seek immediate medical attention [see Contraindications (4.1) and Warnings and Precautions (5.1)].17.2 Guanylate Cyclase (GC) StimulatorsPhysicians should discuss with patients the contraindication of tadalafil with any use of a GC stimulator, such as riociguat, for pulmonary arterial hypertension.

Side Effect Severity Common Symptoms Frequency Recommended Action
Headache Mild Throbbing head Common Hydrate, rest
Flushing Mild Warm sensation Common Cooling measures
Dizziness Moderate Lightheadedness Less common Sit or lie down
Vision Changes Mild Blur or blue tint Less common Seek medical help if persistent

Patients should be counseled that the concomitant use of tadalafil with GC stimulators may cause blood pressure to drop to an unsafe level.17.3 Cardiovascular ConsiderationsPhysicians should consider the potential cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Physicians should advise patients who experience symptoms upon initiation of sexual activity to refrain from further sexual activity and seek immediate medical attention [see Warnings and Precautions (5.1)].17.4 Concomitant Use with Drugs Which Lower Blood PressurePhysicians should discuss with patients the potential for tadalafil to augment the blood-pressure-lowering effect of alpha-blockers, and antihypertensive medications [see Warnings and Precautions (5.6), Drug Interactions (7.1), and Clinical Pharmacology (12.2)].17.5 Potential for Drug Interactions When Taking Tadalafil Tablets for Once Daily UsePhysicians should discuss with patients the clinical implications of continuous exposure to tadalafil when prescribing tadalafil tablets for once daily use, especially the potential for interactions with medications (e.g., nitrates, alpha-blockers, antihypertensives and potent inhibitors of cytochrome P450 3A4) and with substantial consumption of alcohol [see Dosage and Administration (2.7), Warnings and Precautions (5.6), Drug Interactions (7.1, 7.2), Clinical Pharmacology (12.2), and Clinical Studies (14.2)].17.6 PriapismThere have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.